VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
VolitionRx (VNRX) reported third-quarter 2026 revenue of approximately $1.6 million, reflecting increased recognition of deferred revenue as losses narrowed. Revenue rose 157% year over year. Operating loss narrowed to $3.3 million from $5.1 million, and net loss narrowed to $3.8 million from $5.4 million. Operating expenses fell 14%. Cash was approximately $2.4 million at September 30, versus $1.1 million at year-end 2025. Quarterly financing included approximately $5.2 million in net at-the-market proceeds; Volition also prepaid the outstanding balance of its $7.5 million convertible note in cash.
Business developments included sepsis research and an October letter of intent with Missionpharma. Volition expects a French lung-cancer reimbursement submission and publication of its feline assay study in the fourth quarter. Peer-reviewed evidence of feline clinical utility is required to unlock a $5 million milestone payment.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointApproximately $5.2 million in net proceeds came from the at-the-market facility during the third quarter. 85% of market cap
- Major pointConvertible-note debt reduced through cash prepayment of the outstanding balance of the $7.5 million note. 1.2× market cap
- Moderate pointThird-quarter revenue rose 157% to approximately $1.6 million, reflecting increased recognition of deferred revenue.
- Moderate pointOperating loss narrowed 35% to $3.3 million, versus $5.1 million in third-quarter 2025.
- Moderate pointNet loss narrowed to $3.8 million from $5.4 million, including $0.4 million in non-cash convertible-note charges.
- Moderate pointOperating expenses fell 14% year over year; the cost-reduction program included a 28% headcount reduction.
- Moderate pointCash increased to approximately $2.4 million at September 30, 2026, from $1.1 million at December 31, 2025.
- Moderate point€6.3 million DETECSEPS program launched, evaluating Nu.Q NETs as the sole biomarker for early sepsis detection.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Missionpharma letter of intent signed in October; Volition expects initial efforts to focus on neonatal-sepsis triage and prognosis.
10 minor points
- Minor pointPublished sepsis data identified Nu.Q NETs H3.1 as an independent predictor of 28-day mortality and renal-replacement needs.
- Minor pointPublished clinical data indicate Nu.Q NETs distinguishes sepsis from non-infectious inflammation and provides organ-failure and mortality prognostic value.
- Minor pointPoint-of-care prototype demonstrated high correlation with the CE-marked automated assay in ICU sepsis patients.
- Minor pointSysmex and Werfen collaborations continue to advance across NETs-related indications, Volition said.
- Minor point. Forward-looking: it has not happened yet and may not happen.French Nu.Q Lung Cancer reimbursement submission is expected in the fourth quarter of 2026.
- Minor pointCapture-Seq licensing discussions are active with several liquid-biopsy and diagnostic companies following August clinical-data publication.
- Minor pointFeline prototype detected 86% of lymphomas at 97% specificity in a manuscript submitted for peer review.
- Minor point. Forward-looking: it has not happened yet and may not happen.Feline study publication is anticipated in the fourth quarter of 2026.
- Minor pointCEO annual base salary reduced to 50% of its original level effective November 1, until a substantial licensing agreement.
- Minor point. Forward-looking: it has not happened yet and may not happen.Chairman and entire board agreed to reduce cash fees by at least 50%.
Negative
- Major pointAt-the-market share sales that generated approximately $5.2 million in net proceeds dilute existing shareholders. 85% of market cap
- Moderate pointMissionpharma arrangement remains a letter of intent, rather than a completed commercial agreement.
- Moderate point$5 million feline milestone payment requires a peer-reviewed publication evidencing clinical utility. 82% of market cap
News Explained
The CEO’s annual base salary is now
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference call to discuss financial and operational results scheduled for
Friday, November 13 at 8:30 a.m.
Cameron Reynolds, President and Group Chief Executive Officer, said:
"It has been a very full quarter as we have continued to execute our plan to commercialize our game-changing Nu.Q® platform. We have made strong progress across our key product pillars this year, evidencing clinical utility across a broad spectrum of indications whilst driving commercialization and licensing efforts worldwide. At the same time, we have taken decisive action to strengthen our financial profile by cutting costs and significantly reducing convertible note debt.
"In our Nu.Q® NETs pillar, in September we participated in the launch of DETECSEPS, a French government-funded
"Furthermore, our rapid point-of-care finger-prick lateral flow prototype has demonstrated high correlation with our CE-marked automated assay in ICU sepsis patients. To accelerate commercialization and global market access, particularly in resource-constrained countries and humanitarian emergency settings, we signed in October a Letter of Intent with Missionpharma, a global distributor of healthcare products serving over 100 million patients annually. Initial efforts with Missionpharma are expected to focus on triaging and prognostication for neonatal sepsis. In parallel, our diagnostic collaborations with Sysmex Corporation and Werfen's Immunoassay Technology Center continue to advance across NETs-related indications.
"In Nu.Q® Cancer, we are advancing toward our French reimbursement submission for Nu.Q® Lung Cancer with support from our long-term collaborators at Hospices Civils de
"In our Nu.Q® Vet pillar, our clinical manuscript, submitted for peer review in May, demonstrated that our feline prototype assay detected
"I am personally leading our most advanced partner negotiations and, to underline my commitment to closing them, have voluntarily agreed to a further reduction in my base salary, effective November 1, 2026, such that my annual base salary is now
Financial Highlights for the Third Quarter 2026
- Revenue: Third quarter 2026 revenue was approximately
$1.6 million 157% compared to$0.6 million - Operating Expenses: Operating expenses for the third quarter of 2026 were
14% lower than the same period in 2025, reflecting savings from Volition's ongoing cost-reduction program, including a28% reduction in headcount compared to the same point last year. - Operating Loss: Operating loss for the third quarter of 2026 narrowed to
$3.3 million 35% improvement compared to$5.1 million - Net Loss: Net loss for the third quarter of 2026 was
$3.8 million $0.4 million $5.4 million - Balance Sheet & Debt Reduction: Cash and cash equivalents totaled approximately
$2.4 million $1.1 million $5.2 million $7.5 million
Event: VolitionRx Limited Third Quarter 2026 Earnings and Business Update Conference Call
Date: Friday, November 13, 2026
Time: 8:30 a.m.
Toll/International: 1-201-493-6779
Conference ID: 13763536
Rodney Rootsaert, Corporate Secretary, VolitionRx will host the call along with Cameron Reynolds, President and Group Chief Executive Officer and Terig Hughes, Group Chief Financial Officer. The call will provide an update on important events that have taken place in the third quarter of 2026, subsequent events and upcoming milestones.
A live audio webcast of the conference call will also be available on this link. In addition, a telephone replay of the call will be available until November 27, 2026. The replay dial-in numbers are 1-844-512-2921 (toll-free) in the
Notes:
- Volition internal estimate based on VNRX TAM Model
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
The contents found at Volition's website address, www.volition.com, are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Ellen Amonoo, Volition, mediarelations@volition.com
Safe Harbor Statement
Statements contained in this press release and made on the related conference call may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are those that are not statements of historical fact and instead address predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "continue," "project," "could," "would," "should," "may," "will" and similar expressions identify such statements.
These forward-looking statements relate to, among other topics, Volition's expectations regarding revenue opportunities and growth; the effectiveness and availability of its blood-based diagnostic, prognostic and disease monitoring tests; its ability to develop and successfully commercialize such test platforms for the early detection and monitoring of cancer and other diseases; its expectations regarding future publications and the related milestone payment; the timing and outcome of its reimbursement submission in France and the DETECSEPS program; estimates of addressable markets; its cost-reduction plans; its liquidity, capital needs and ability to fund operations; and its success in securing, and the terms of, licensing and/or distribution or other agreements with third parties, including a definitive agreement with Missionpharma.
Forward-looking statements are based on current expectations, estimates and projections about Volition's business, in part on assumptions made by management. They are not guarantees of future performance and involve risks and uncertainties that are difficult to predict and that could cause actual results to differ materially from those anticipated. These risks and uncertainties include, without limitation: Volition's need for additional financing, which may not be available on acceptable terms or at all, the uncertain timing of publication of Volition's feline lymphoma study; the timing and outcome of Volition's reimbursement submission in France and of the DETECSEPS program; Volition's dependence on key collaborators and distributors, including Sysmex Corporation, Werfen, Missionpharma and Hospices Civils de Lyon; the assumptions underlying Volition's addressable market estimates; the results of studies testing the efficacy of Volition's tests; failure to develop and commercialize its products, which may prevent it from executing its plan of operations; failure to obtain necessary regulatory clearances or approvals; failure to achieve healthcare system or insurance reimbursement; failure of the marketplace to accept its products; failure to secure adequate intellectual property protection; the highly competitive and rapidly evolving nature of the diagnostics and disease monitoring market, which may render its products obsolete; downturns in domestic and foreign economies; and other risks identified in Volition's most recent Annual Report on Form 10-K, its Quarterly Reports on Form 10-Q, and other documents filed with the Securities and Exchange Commission.
Forward-looking statements are made as of the date hereof and, except as required by law, Volition undertakes no obligation to update them to reflect future events or circumstances.
Nu.Q®, Nucleosomics™, Capture-PCR™, Capture-Seq™ and rNuQ™ and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of the United States of America.
View original content:https://www.prnewswire.com/news-releases/volitionrx-limited-announces-third-quarter-2026-financial-results-and-business-update-302938119.html
SOURCE VolitionRx Limited
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were VolitionRx's third-quarter 2026 financial results?
VolitionRx reported approximately $1.6 million in revenue, an operating loss of $3.3 million and a net loss of $3.8 million. Revenue increased 157% from third-quarter 2025, while operating loss improved 35%. The net loss included $0.4 million in non-cash charges related to convertible notes.
How much cash did VolitionRx have after the third quarter of 2026?
VolitionRx had approximately $2.4 million in cash and cash equivalents at September 30, 2026, compared with $1.1 million at December 31, 2025. Third-quarter receipts included approximately $5.2 million in net at-the-market proceeds. During the quarter, it also prepaid in cash the outstanding balance of its $7.5 million convertible note.